Data From Phase III Extension Trial Show Long-Term Safety, Efficacy of Qulipta in Migraine Prevention; Multicenter, open-label, 156-week extension trial finds that Qulipta (atogepant) reduced migraine days and acute medication use in patients with chronic

Media coverage

• Title	Data From Phase III Extension Trial Show Long-Term Safety, Efficacy of Qulipta in Migraine Prevention; Multicenter, open-label, 156-week extension trial finds that Qulipta (atogepant) reduced migraine days and acute medication use in patients with chronic
  Media name/outlet	Applied Clinical Trials
  Country/Territory	United States
  Date	12/04/24
  Persons	Sait Ashina